vs
Side-by-side financial comparison of Dover Corporation (DOV) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Dover Corporation is the larger business by last-quarter revenue ($2.1B vs $1.1B, roughly 1.9× PERRIGO Co plc). Dover Corporation runs the higher net margin — 13.4% vs -127.8%, a 141.2% gap on every dollar of revenue. On growth, Dover Corporation posted the faster year-over-year revenue change (12.5% vs -2.5%). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -1.8%).
Dover Corporation is an American conglomerate manufacturer of industrial products. The Downers Grove, Illinois-based company was founded in 1955. As of 2021, Dover's business was divided into five segments: Engineered Products, Clean Energy and Fueling, Imaging & Identification, Pumps & Process Solutions and Climate and Sustainability Technologies. Dover is a constituent of the S&P 500 index and trades on the New York Stock Exchange under the symbol DOV. Dover was ranked 448 in the 2024 Fortu...
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
DOV vs PRGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.1B | $1.1B |
| Net Profit | $282.1M | $-1.4B |
| Gross Margin | 39.1% | 32.6% |
| Operating Margin | 16.5% | -116.0% |
| Net Margin | 13.4% | -127.8% |
| Revenue YoY | 12.5% | -2.5% |
| Net Profit YoY | 22.2% | -3093.9% |
| EPS (diluted) | $2.06 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $1.1B | ||
| Q3 25 | $2.1B | $1.0B | ||
| Q2 25 | $2.0B | $1.1B | ||
| Q1 25 | $1.9B | $1.0B | ||
| Q4 24 | $1.5B | $1.1B | ||
| Q3 24 | $2.0B | $1.1B | ||
| Q2 24 | $2.2B | $1.1B |
| Q1 26 | $282.1M | — | ||
| Q4 25 | $282.1M | $-1.4B | ||
| Q3 25 | $302.0M | $7.5M | ||
| Q2 25 | $279.1M | $-8.4M | ||
| Q1 25 | $230.8M | $-6.4M | ||
| Q4 24 | $1.4B | $-44.4M | ||
| Q3 24 | $347.1M | $-21.0M | ||
| Q2 24 | $281.8M | $-108.4M |
| Q1 26 | 39.1% | — | ||
| Q4 25 | 39.1% | 32.6% | ||
| Q3 25 | 40.1% | 36.1% | ||
| Q2 25 | 39.9% | 34.4% | ||
| Q1 25 | 40.0% | 37.6% | ||
| Q4 24 | 41.4% | 33.9% | ||
| Q3 24 | 38.5% | 37.2% | ||
| Q2 24 | 37.7% | 37.0% |
| Q1 26 | 16.5% | — | ||
| Q4 25 | 16.5% | -116.0% | ||
| Q3 25 | 18.2% | 7.0% | ||
| Q2 25 | 17.3% | 4.3% | ||
| Q1 25 | 15.9% | 4.5% | ||
| Q4 24 | 14.0% | 10.0% | ||
| Q3 24 | 16.8% | 7.4% | ||
| Q2 24 | 17.0% | -2.5% |
| Q1 26 | 13.4% | — | ||
| Q4 25 | 13.4% | -127.8% | ||
| Q3 25 | 14.5% | 0.7% | ||
| Q2 25 | 13.6% | -0.8% | ||
| Q1 25 | 12.4% | -0.6% | ||
| Q4 24 | 96.4% | -3.9% | ||
| Q3 24 | 17.5% | -1.9% | ||
| Q2 24 | 12.9% | -10.2% |
| Q1 26 | $2.06 | — | ||
| Q4 25 | $2.06 | $-10.23 | ||
| Q3 25 | $2.19 | $0.05 | ||
| Q2 25 | $2.02 | $-0.06 | ||
| Q1 25 | $1.67 | $-0.05 | ||
| Q4 24 | $10.38 | $-0.32 | ||
| Q3 24 | $2.51 | $-0.15 | ||
| Q2 24 | $2.04 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $3.3B | — |
| Stockholders' EquityBook value | $7.4B | $2.9B |
| Total Assets | $13.4B | $8.5B |
| Debt / EquityLower = less leverage | 0.45× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $432.1M | ||
| Q2 25 | — | $454.2M | ||
| Q1 25 | — | $409.9M | ||
| Q4 24 | — | $558.8M | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $542.8M |
| Q1 26 | $3.3B | — | ||
| Q4 25 | $3.3B | — | ||
| Q3 25 | $3.1B | — | ||
| Q2 25 | $3.1B | — | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $2.9B | — | ||
| Q3 24 | $3.0B | — | ||
| Q2 24 | $3.0B | — |
| Q1 26 | $7.4B | — | ||
| Q4 25 | $7.4B | $2.9B | ||
| Q3 25 | $7.7B | $4.4B | ||
| Q2 25 | $7.4B | $4.5B | ||
| Q1 25 | $7.1B | $4.4B | ||
| Q4 24 | $7.0B | $4.3B | ||
| Q3 24 | $5.7B | $4.6B | ||
| Q2 24 | $5.4B | $4.5B |
| Q1 26 | $13.4B | — | ||
| Q4 25 | $13.4B | $8.5B | ||
| Q3 25 | $13.4B | $10.1B | ||
| Q2 25 | $13.2B | $10.1B | ||
| Q1 25 | $12.6B | $9.8B | ||
| Q4 24 | $12.5B | $9.6B | ||
| Q3 24 | $11.9B | $11.2B | ||
| Q2 24 | $11.3B | $10.4B |
| Q1 26 | 0.45× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.40× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.42× | — | ||
| Q4 24 | 0.42× | — | ||
| Q3 24 | 0.53× | — | ||
| Q2 24 | 0.55× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.4M |
| Free Cash FlowOCF − Capex | — | $148.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $543.9M | $175.4M | ||
| Q3 25 | $424.2M | $51.7M | ||
| Q2 25 | $212.3M | $75.9M | ||
| Q1 25 | $157.5M | $-64.5M | ||
| Q4 24 | $439.0M | $312.6M | ||
| Q3 24 | $353.2M | $42.2M | ||
| Q2 24 | $203.7M | $9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $487.0M | $148.6M | ||
| Q3 25 | $370.1M | $29.8M | ||
| Q2 25 | $151.4M | $56.7M | ||
| Q1 25 | $109.3M | $-90.0M | ||
| Q4 24 | $385.0M | $274.9M | ||
| Q3 24 | $325.0M | $15.1M | ||
| Q2 24 | $162.8M | $-18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 23.2% | 13.4% | ||
| Q3 25 | 17.8% | 2.9% | ||
| Q2 25 | 7.4% | 5.4% | ||
| Q1 25 | 5.9% | -8.6% | ||
| Q4 24 | 25.8% | 24.2% | ||
| Q3 24 | 16.4% | 1.4% | ||
| Q2 24 | 7.5% | -1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 2.4% | ||
| Q3 25 | 2.6% | 2.1% | ||
| Q2 25 | 3.0% | 1.8% | ||
| Q1 25 | 2.6% | 2.4% | ||
| Q4 24 | 3.6% | 3.3% | ||
| Q3 24 | 1.4% | 2.5% | ||
| Q2 24 | 1.9% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.93× | — | ||
| Q3 25 | 1.40× | 6.89× | ||
| Q2 25 | 0.76× | — | ||
| Q1 25 | 0.68× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.02× | — | ||
| Q2 24 | 0.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOV
Segment breakdown not available.
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
